1. An 80-year-old man with chronic kidney disease (CKD) and an estimated glomerular filtration rate (eGFR) of 28 mL/min/1.73m2 has been taking glyburide. During a febrile illness he eats poorly for two days and presents with hypoglycemia. After initial correction with oral carbohydrate, he becomes hypoglycemic again three hours later. Which combination of factors best explains this recurrent, prolonged hypoglycemia and the appropriate disposition?
A) Glyburide's rapid clearance produces brief hypoglycemia, so discharge after a single correction is appropriate
B) Accumulation of glyburide's weakly active metabolites in renal impairment, combined with glucose-independent insulin secretion, sustains insulin release as glucose normalizes, warranting hospital admission with continuous dextrose until drug clearance
C) The hypoglycemia reflects metformin-associated lactic acidosis and should be treated with bicarbonate rather than dextrose
D) Glyburide stimulates insulin only when glucose is elevated, so the recurrence must be due to an unrelated insulinoma
E) The renal impairment accelerates glyburide elimination, so the recurrence is unrelated to the drug
ANSWER: B
Rationale:
Glyburide is metabolized to weakly active metabolites that accumulate as renal function declines; combined with the glucose-independent nature of sulfonylurea-induced insulin secretion, residual drug continues to drive insulin release even as glucose recovers, producing prolonged and recurrent hypoglycemia. This warrants hospital admission with continuous intravenous dextrose until drug clearance is complete.
Option A: Option A is incorrect because glyburide and its metabolites accumulate and act for a prolonged period in CKD, so a single correction and discharge is unsafe.
Option C: Option C is incorrect because the picture is recurrent hypoglycemia from a secretagogue, not lactic acidosis, and dextrose rather than bicarbonate is the relevant therapy.
Option D: Option D is incorrect because sulfonylurea secretion is glucose-independent, which is precisely why hypoglycemia persists; an insulinoma need not be invoked.
Option E: Option E inverts the renal effect: impairment causes accumulation and prolonged action, not accelerated elimination.
2. A patient stabilized on a sulfonylurea is started on a second drug that, like the sulfonylurea, is more than 90 percent bound to albumin. Shortly afterward the patient experiences an episode of hypoglycemia despite no change in sulfonylurea dose. Which mechanism best accounts for this?
A) The new drug induced CYP2C9, accelerating sulfonylurea metabolism and lowering glucose
B) The new drug blocked renal excretion of glucose, producing hypoglycemia independent of the sulfonylurea
C) The new drug increased sulfonylurea protein binding, raising the bound fraction and its activity
D) The new drug displaced the sulfonylurea from albumin binding sites, transiently raising the free (active) sulfonylurea concentration and increasing its hypoglycemic effect
E) The new drug closed the KATP channel directly, adding to the sulfonylurea effect through an identical receptor action
ANSWER: D
Rationale:
Sulfonylureas are highly albumin-bound (greater than 90 percent), so a co-administered drug that is also highly protein-bound can displace the sulfonylurea from albumin, transiently increasing the free (pharmacologically active) sulfonylurea concentration and intensifying its hypoglycemic effect.
Option A: Option A is incorrect because enzyme induction would lower, not raise, sulfonylurea exposure and would not produce acute hypoglycemia.
Option B: Option B describes an SGLT-2-type renal glucose effect, which is not the protein-binding mechanism described.
Option C: Option C inverts the effect: displacement decreases the bound fraction and raises the free active fraction.
Option E: Option E is incorrect because the interaction is pharmacokinetic displacement, not a second drug acting on the KATP channel.
3. A patient taking repaglinide for postprandial glucose control is referred for management of severe hypertriglyceridemia, and gemfibrozil is proposed. Integrating repaglinide's metabolism with gemfibrozil's enzyme effect, what is the correct conclusion?
A) The combination is contraindicated because gemfibrozil inhibits CYP2C8, raising repaglinide exposure approximately eight-fold and producing severe hypoglycemia
B) The combination is safe because repaglinide is eliminated renally and gemfibrozil affects only hepatic drugs
C) Gemfibrozil will lower repaglinide levels by inducing CYP3A4, requiring a repaglinide dose increase
D) The two drugs do not interact because repaglinide is not metabolized by cytochrome P450 enzymes
E) Gemfibrozil displaces repaglinide from albumin, an interaction managed simply by separating the doses by two hours
ANSWER: A
Rationale:
Gemfibrozil is a potent inhibitor of CYP2C8 (cytochrome P450 2C8), a primary enzyme for repaglinide metabolism; co-administration raises repaglinide AUC (area under the curve) approximately eight-fold, creating a severe hypoglycemia risk, so the combination is contraindicated.
Option B: Option B is incorrect because repaglinide is hepatically metabolized (predominantly biliary elimination), not renally cleared, and is therefore subject to this hepatic enzyme interaction.
Option C: Option C inverts the effect: gemfibrozil inhibits rather than induces the relevant enzyme, raising exposure rather than lowering it.
Option D: Option D is incorrect because repaglinide is metabolized by CYP3A4 and CYP2C8, so a P450 interaction is exactly what occurs.
Option E: Option E is incorrect because the interaction is metabolic enzyme inhibition with a large exposure increase, not a protein-binding displacement that dose separation would solve.
4. A patient with long-standing type 2 diabetes mellitus (T2DM) has lost first-phase insulin secretion, yet a sulfonylurea still produces a measurable glucose-lowering response. Which integration of mechanism and pathophysiology best explains this retained efficacy?
A) Sulfonylureas work only when first-phase insulin secretion is intact, so the response must reflect a laboratory error
B) Sulfonylureas restore glucose sensing in the beta cell by repairing the glycolytic pathway
C) Sulfonylureas act on hepatic gluconeogenesis rather than the beta cell, so beta cell status is irrelevant
D) Sulfonylureas stimulate new beta cell proliferation, regenerating lost secretory capacity
E) Sulfonylureas close the KATP channel by binding SUR1 independently of glucose metabolism, so they retain efficacy when glucose sensing is impaired but SUR1 expression is intact
ANSWER: E
Rationale:
Because sulfonylureas stabilize the closed state of the KATP channel by binding SUR1 without requiring elevated intracellular glucose metabolism, they retain efficacy in advanced T2DM where first-phase glucose-stimulated secretion is lost but SUR1 expression remains intact.
Option A: Option A is incorrect because sulfonylurea action does not depend on intact first-phase secretion; that is the very point of the glucose-independent mechanism.
Option B: Option B is incorrect because sulfonylureas do not repair the glycolytic glucose-sensing pathway; they bypass the need for it.
Option C: Option C is incorrect because sulfonylureas act on the beta cell KATP channel, not on hepatic gluconeogenesis.
Option D: Option D is incorrect because sulfonylureas do not regenerate beta cells; chronic use is associated with beta cell exhaustion rather than proliferation.
5. A patient with CKD and an unpredictable, irregular meal schedule requires an insulin secretagogue. Integrating dosing design with elimination route, which choice is best and why?
A) Glyburide, because its long duration covers meals taken at any time without dose adjustment
B) Chlorpropamide, because its very long half-life smooths out irregular eating
C) Repaglinide, because its dose-per-meal design suits irregular meals and its predominantly biliary elimination avoids the metabolite accumulation that sulfonylureas show in CKD
D) Any second-generation sulfonylurea, because all are equally safe in CKD when meals are irregular
E) Nateglinide at a fixed once-daily dose, because its long action covers all meals from a single morning dose
ANSWER: C
Rationale:
Repaglinide is dosed before each meal and omitted when a meal is skipped, which matches an irregular eating pattern, and its predominantly hepatic/biliary elimination (less than 10 percent renal) avoids the renal metabolite accumulation that makes sulfonylureas hazardous in CKD.
Option A: Option A is incorrect because glyburide's long duration and renally accumulating active metabolites make it dangerous in CKD, not advantageous.
Option B: Option B is incorrect because chlorpropamide's very long half-life increases hypoglycemia risk and does not address irregular meals safely.
Option D: Option D is incorrect because sulfonylureas are not all equally safe in CKD; glyburide in particular is hazardous.
Option E: Option E is incorrect because nateglinide is a short-acting prandial agent dosed before each meal, not a once-daily long-acting drug.
6. Two agents are compared: metformin and a meglitinide. The metformin-treated patient shows the greatest improvement in fasting plasma glucose, while the meglitinide-treated patient shows the greatest improvement in postprandial glucose. Which integration of mechanisms explains this difference in glycemic targeting?
A) Metformin's dominant effect is suppression of hepatic gluconeogenesis, which preferentially lowers fasting glucose, whereas the meglitinide produces a short prandial insulin burst that preferentially lowers postprandial glucose
B) Metformin is a prandial secretagogue and the meglitinide suppresses hepatic glucose output, so the targeting is reversed
C) Both drugs act identically on the beta cell KATP channel, so any difference reflects dosing time alone
D) Metformin lowers fasting glucose by stimulating insulin secretion overnight, while the meglitinide blocks intestinal glucose absorption after meals
E) The meglitinide lowers fasting glucose through a long half-life, while metformin lowers postprandial glucose by closing the KATP channel
ANSWER: A
Rationale:
Metformin's dominant glycemic effect is suppression of hepatic glucose production, which preferentially lowers fasting plasma glucose, while a meglitinide produces a brief, meal-timed insulin secretory burst that preferentially lowers postprandial glucose. The contrasting targets follow directly from the two mechanisms.
Option B: Option B inverts the mechanisms of the two drugs.
Option C: Option C is incorrect because metformin does not act on the beta cell KATP channel; the drugs have distinct mechanisms, not identical ones.
Option D: Option D is incorrect because metformin is not an overnight secretagogue and the meglitinide is a secretagogue rather than an absorption blocker.
Option E: Option E inverts both the targeting and the mechanisms.
7. A patient adherent to metformin has therapeutic plasma drug concentrations but a poor HbA1c (glycated hemoglobin) response. Genetic testing reveals two reduced-function OCT1 (organic cation transporter 1) alleles. Integrating transporter biology with metformin's site of action, which conclusion follows?
A) The therapeutic plasma level proves the drug is working, so the poor response must reflect non-adherence
B) Reduced OCT1 function increases renal clearance, so the plasma level reported must be erroneous
C) OCT1 variants alter beta cell insulin secretion, so the patient should be switched to a higher sulfonylurea dose
D) Reduced OCT1 function limits hepatic uptake of metformin, so the drug cannot adequately reach its intracellular hepatic site of action despite adequate plasma concentrations, blunting the glucose-lowering response
E) OCT1 variants accelerate metformin metabolism in the liver, lowering the effective hepatic concentration
ANSWER: D
Rationale:
OCT1 mediates hepatic uptake of metformin, the step required for it to reach its intracellular site of action. With two reduced-function OCT1 alleles, hepatic uptake is diminished, so the drug cannot adequately act on hepatocyte gluconeogenesis even when plasma concentrations are therapeutic, producing a blunted HbA1c response.
Option A: Option A is incorrect because adequate plasma level does not guarantee hepatic delivery; the uptake defect explains the poor response without invoking non-adherence.
Option B: Option B is incorrect because the issue is reduced hepatic uptake, not erroneous plasma measurement or increased renal clearance.
Option C: Option C is incorrect because OCT1 governs hepatic uptake, not beta cell secretion, so escalating a sulfonylurea does not address the mechanism.
Option E: Option E is incorrect because metformin is not metabolized; the defect is in transporter-mediated hepatic uptake, not accelerated metabolism.
8. A patient on metformin with a borderline eGFR of 48 mL/min/1.73m2 is scheduled for a contrast-enhanced CT using iodinated contrast. Integrating metformin's clearance route with the renal effect of contrast, what is the correct management and rationale?
A) Continue metformin unchanged, since its hepatic metabolism makes contrast irrelevant
B) Hold metformin at the time of the procedure and withhold it for 48 hours pending a renal recheck, because metformin is cleared entirely by the kidney and contrast-induced acute kidney injury could shift the eGFR into the contraindicated range while drug accumulates in tissue
C) Double the metformin dose beforehand to maintain glycemic control during the renal stress of contrast
D) Stop metformin permanently, since any contrast exposure is an absolute lifelong contraindication to the drug
E) Switch to glyburide for the periprocedural period, since sulfonylureas are safer than metformin during contrast exposure in CKD
ANSWER: B
Rationale:
Metformin is cleared entirely by the kidney, so contrast-induced acute kidney injury could rapidly lower the eGFR into the contraindicated range while metformin accumulates in tissue, raising the risk of drug and lactate accumulation. The correct management is to hold metformin at the time of the procedure and withhold it for 48 hours pending a renal recheck.
Option A: Option A is incorrect because metformin is renally cleared and not hepatically metabolized, so contrast is highly relevant.
Option C: Option C is incorrect because increasing the dose before a potential renal insult worsens the accumulation risk.
Option D: Option D is incorrect because the hold is temporary pending renal recheck, not a permanent lifelong contraindication.
Option E: Option E is incorrect because glyburide is hazardous in CKD due to metabolite accumulation and is not a safer periprocedural substitute.
9. A patient on metformin for eight years, also taking a proton pump inhibitor (PPI) for reflux, develops a macrocytic anemia and worsening distal sensory neuropathy that had been attributed to diabetes. Integrating metformin's effect with the concurrent PPI, which explanation and action is most appropriate?
A) The neuropathy is purely diabetic and unrelated to medications, so no further workup is warranted
B) The macrocytosis reflects metformin-induced folate deficiency, treated by stopping the PPI alone
C) The findings reflect iron deficiency from metformin chelation of dietary iron, treated with iron alone
D) The anemia is hemolytic from a metformin-PPI interaction and requires corticosteroids
E) Long-term metformin impairs ileal absorption of the vitamin B12-intrinsic factor complex, and the PPI further reduces intrinsic factor availability, so vitamin B12 should be measured and the deficiency, which can mimic or worsen diabetic neuropathy, corrected
ANSWER: E
Rationale:
Long-term metformin impairs the calcium-dependent ileal absorption of the vitamin B12-intrinsic factor complex, and concurrent PPI use further reduces intrinsic factor availability, compounding the deficiency. B12 deficiency produces macrocytic anemia and a peripheral neuropathy that can mimic or worsen diabetic polyneuropathy, so B12 should be measured and corrected.
Option A: Option A is incorrect because attributing the neuropathy solely to diabetes overlooks a treatable, drug-related B12 deficiency.
Option B: Option B is incorrect because metformin depletes vitamin B12, not folate, and stopping the PPI alone does not address the established deficiency.
Option C: Option C is incorrect because metformin does not cause iron deficiency by chelating dietary iron.
Option D: Option D is incorrect because the anemia is a macrocytic deficiency anemia, not a hemolytic process requiring corticosteroids.
10. A patient on metformin is admitted with septic shock and acute kidney injury. The team is concerned about metformin-associated lactic acidosis (MALA). Integrating metformin's effect on lactate handling with the physiology of sepsis, why does this clinical context maximize MALA risk?
A) Sepsis increases renal metformin clearance, so drug levels fall and lactate cannot accumulate
B) Metformin raises blood glucose in sepsis, and the hyperglycemia directly generates lactic acid
C) Metformin impairs hepatic and renal lactate clearance through complex I inhibition, while sepsis and shock simultaneously increase lactate production and reduce metformin clearance through acute kidney injury, so accumulation converges from both directions
D) Metformin protects against lactic acidosis in sepsis by stimulating mitochondrial oxidative phosphorylation
E) The risk is unrelated to metformin because lactic acidosis in sepsis is always purely from tissue hypoperfusion
ANSWER: C
Rationale:
Metformin inhibits complex I, impairing hepatic and renal lactate clearance, while septic shock simultaneously increases lactate production and, through acute kidney injury, reduces metformin clearance and promotes drug accumulation. These factors converge to maximize MALA risk in this setting.
Option A: Option A is incorrect because acute kidney injury reduces, not increases, metformin clearance, promoting accumulation.
Option B: Option B is incorrect because MALA arises from impaired lactate clearance, not from hyperglycemia generating lactic acid.
Option D: Option D inverts metformin's effect: it inhibits complex I rather than stimulating oxidative phosphorylation, so it does not protect against lactic acidosis.
Option E: Option E is incorrect because, although sepsis itself causes lactate from hypoperfusion, accumulated metformin compounds the problem by impairing clearance, so the risk is not unrelated to the drug.
11. A newly diagnosed T2DM patient presents with an HbA1c of 9.8 percent and significant financial constraints that preclude GLP-1 (glucagon-like peptide-1) receptor agonists or SGLT-2 (sodium-glucose cotransporter-2) inhibitors. Integrating the ADA early-combination principle with the role of secretagogues, which initial strategy is most consistent with current guidance?
A) Initiate combination therapy from the outset—metformin plus a sulfonylurea—because a markedly elevated HbA1c is unlikely to reach target on monotherapy and the low cost of a generic sulfonylurea fits the financial constraints
B) Initiate metformin monotherapy alone and wait at least one year before considering any second agent regardless of response
C) Initiate a GLP-1 receptor agonist despite the cost, since guidelines forbid sulfonylureas at any HbA1c
D) Initiate a sulfonylurea alone without metformin, since metformin is contraindicated at high HbA1c
E) Defer all pharmacotherapy and rely on lifestyle modification alone until HbA1c falls below 8 percent
ANSWER: A
Rationale:
For patients presenting with an HbA1c greater than 9 percent, ADA guidance supports initiating combination therapy rather than monotherapy, because monotherapy is unlikely to reach target in this range; in a cost-constrained patient, adding a low-cost generic sulfonylurea to metformin is consistent with the secretagogue's guideline-defined role in cost-sensitive prescribing.
Option B: Option B is incorrect because a markedly elevated HbA1c calls for early combination, not a mandatory year of monotherapy.
Option C: Option C is incorrect because guidelines do not forbid sulfonylureas; they retain a defined role, particularly when cost precludes other agents.
Option D: Option D is incorrect because metformin is not contraindicated by a high HbA1c and remains the backbone agent.
Option E: Option E is incorrect because lifestyle alone is inadequate at an HbA1c of 9.8 percent and pharmacotherapy should be initiated promptly.
12. A patient has near-normal fasting glucose but pronounced postprandial hyperglycemia. Integrating nateglinide's binding kinetics with this glycemic pattern, why is nateglinide a pharmacologically rational choice?
A) Nateglinide has the slowest dissociation from SUR1 of any secretagogue, giving sustained 24-hour coverage that flattens fasting glucose
B) Nateglinide suppresses hepatic gluconeogenesis, which is the dominant driver of postprandial glucose
C) Nateglinide blocks intestinal glucose absorption, so it has no effect on insulin secretion
D) Nateglinide has the fastest dissociation from SUR1, producing a short, low-amplitude insulin burst timed to the meal, which matches an abnormality confined largely to the postprandial period with preserved fasting glucose
E) Nateglinide produces the largest HbA1c reduction of all oral agents, making it the choice whenever any hyperglycemia is present
ANSWER: D
Rationale:
Nateglinide has an even faster dissociation rate from SUR1 than repaglinide, producing a short, low-amplitude insulin secretory response timed to the meal; this narrow prandial targeting is pharmacologically matched to a patient whose abnormality is largely postprandial with preserved fasting glucose.
Option A: Option A inverts the kinetics: nateglinide has the fastest, not slowest, dissociation, and it does not provide sustained 24-hour coverage.
Option B: Option B is incorrect because nateglinide is a secretagogue acting on the beta cell, not a suppressor of hepatic gluconeogenesis.
Option C: Option C is incorrect because nateglinide acts by stimulating insulin secretion, not by blocking intestinal glucose absorption.
Option E: Option E is incorrect because nateglinide produces the most modest HbA1c reduction among these agents, not the largest, consistent with its low secretory amplitude.
13. A patient with established atherosclerotic cardiovascular disease (ASCVD) on metformin needs treatment intensification. Cost is not a limiting factor. Integrating the ADA comorbidity-axis framework with the evidence profile of secretagogues, which second agent is preferred and why?
A) A sulfonylurea, because secretagogues are the preferred add-on for patients with established ASCVD
B) A GLP-1 (glucagon-like peptide-1) receptor agonist or SGLT-2 (sodium-glucose cotransporter-2) inhibitor with proven cardiovascular benefit, because on the ASCVD axis these agents are preferred and secretagogues are not preferred for cardiovascular protection
C) A meglitinide, because its short action confers cardiovascular protection in ASCVD
D) Any agent at random, because the comorbidity axes do not influence second-agent selection
E) A sulfonylurea, because the cardiovascular safety controversy has been resolved in favor of secretagogues providing protection
ANSWER: B
Rationale:
In the ADA/EASD comorbidity-axis framework, a patient with established ASCVD should receive an agent with proven cardiovascular benefit—a GLP-1 receptor agonist or an SGLT-2 inhibitor—because these are preferred on the cardiovascular axis, whereas sulfonylureas and meglitinides are not preferred for cardiovascular protection. With cost not limiting, the cardioprotective agents take priority.
Option A: Option A is incorrect because secretagogues are not the preferred add-on on the ASCVD axis.
Option C: Option C is incorrect because meglitinides do not confer cardiovascular protection.
Option D: Option D is incorrect because the comorbidity axes explicitly guide second-agent selection.
Option E: Option E is incorrect because secretagogues have not been shown to provide cardiovascular protection; they remain not preferred on this axis.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.